Zinc monoglycerolate: a slow-release source of zinc with anti-arthritic activity in rats.
Zinc repletion by parental administration of zinc monoglycerolate (ZMG) or certain other lipophilic zinc complexes, suppressed the development of adjuvant-induced polyarthritis in rats. While ZMG was effective when given parenterally over various limited time schedules (immunosuppressant, therapeutic, singledose), it was not effective given orally. The complex showed no acute anti-inflammatory activity in the carrageenan paw oedema assay and little gastric-intestinal or other organ toxicity. When injected s.c. it caused very much less local irritation than most zinc salts. Being lubrous, ZMG could be applied as the dry powder for rubbing into the skin and by this route was found to have anti-arthritic activity. 65Zn was shown to be absorbed and excreted in the faeces (biliary excretion) after applying 65Zn-ZMG dermally to shaved dorsal skin of rats. ZMG showed consistent anti-arthritic activity in rats under conditions in which 2 gold drugs (aurothiomalate, Auranofin) exhibited variable effects, depending on the strain of rat. The role of zinc and its availability in chronic inflammation are discussed on the basis of these studies.
Whitehouse
M W
MW
Department of Pathology, University of Adelaide, South Australia.
Rainsford
K D
KD
Taylor
R M
RM
Vernon-Roberts
B
B
D000818:Animals; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000008:administration & dosage / Q000493:pharmacokinetics / Q000494:pharmacology*; D001169:Arthritis, Experimental / Q000188:drug therapy* / Q000517:prevention & control; D001310:Auranofin / Q000627:therapeutic use; D001682:Biological Availability; D002351:Carrageenan; D003692:Delayed-Action Preparations; D004305:Dose-Response Relationship, Drug; D004487:Edema / Q000139:chemically induced / Q000188:drug therapy / Q000517:prevention & control; D005260:Female; D005990:Glycerol / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000493:pharmacokinetics / Q000494:pharmacology; D007213:Indomethacin / Q000627:therapeutic use; D008297:Male; D009942:Organometallic Compounds / Q000008:administration & dosage / Q000493:pharmacokinetics / Q000494:pharmacology*; D051381:Rats; D011919:Rats, Inbred Strains; D015032:Zinc / Q000008:administration & dosage / Q000493:pharmacokinetics / Q000627:therapeutic use*; D015037:Zinc Radioisotopes
D000894:Anti-Inflammatory Agents, Non-Steroidal; D003692:Delayed-Action Preparations; D009942:Organometallic Compounds; D015037:Zinc Radioisotopes; D001310:Auranofin; C067226:zinc monoglycerolate; D002351:Carrageenan; D015032:Zinc; D005990:Glycerol; D007213:Indomethacin